We are focused on drug discovery & personalized medicine derived from plant-based therapeutics and combination therapies.
The new frontier between medicine and botany.
AWARDED PATENT INHIBITING AUTOPHAGY TO PREVENT & TREAT CANCER
PROVISIONAL PATENT TO TREAT 11 CNS-RELATED VIRUSES & DISEASES*
15+ CELL STUDIES ONCOLOGY & ANTIVIRAL / CNS-RELATED VIRUSES & DISEASES
DCIS Breast Cancer & Cannabinoids
First & only company to be awarded a patent that includes using any molecule, including cannabinoids, as an autophagy inhibitor. Several cell studies and clinical trial with live breast cancer patients.
ONGOING - PHASE I / II
HIV Associated Dementia & Cannabinoids
Several cell studies on the use of cannabinoids to treat HIV affiliated dementia and other central nervous system (CNS) diseases and viruses.
ONGOING - PHASE I / II
Anti-viral Studies to Treat Sepsis
Pre-clinical ant-viral research includes COVID related Sepsis work within a BSL-3 laboratory managed by George Mason University. Focused on using synthetic cannabinoid-based therapeutics to treating Sepsis and infectious diseases.
MEET TARGETED PHARMACEUTICALS
Our goal is to bring precision medicine and real science to the cannabis industry by linking the molecular structure of humans to cannabinoid compounds.
DATA DRIVEN SOLUTIONS
Technology and data are at the core of what we do. We are very much a data-driven technology company focused on using data for personalized cannabinoid care.
TOP TEAM & ADVISORS FROM
TOP TEAM & ADVISORS FROM
George Mason University
National Cancer Institute
Worcester Polytechnic Institute
Food & Drug Adminstration
Oct 22, 2020
Tetra Bio-Pharma, Targeted Pharmaceutical & the George Mason University Partner on ARDS-003 to Prevent & Treat COVID-19
Targeted Pharmaceuticals, Tetra Bio-Pharma and the George Mason University National Center for Biodefense and Infectious Diseases (NCBID) sign a research collaboration
ARDS-003 to be evaluated in Sars-CoV-2 infected animals at the Biocontainment Laboratory-George Mason University NCBID
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is excited to announce that it has signed a research collaboration agreement with Targeted Pharmaceutical and the George Mason University. The research is being conducted at the Biomedical Research Laboratory (BRL) which is managed by the George Mason University National Center for Biodefense and Infectious Diseases (NCBID)
Julu 23, 2019
George Mason University Patent with Applications to Breast Cancer Treatment Licensed by Targeted Pharmaceuticals, a Cannabinoid-Based Drug Discovery Company
Manassas, Va. – A patent granted to George Mason University Research Foundation Inc., which describes a novel treatment method for pre-invasive breast cancer, has been exclusively licensed to Targeted Pharmaceuticals LLC, a clinical-stage biopharmaceutical company focused on utilizing cannabinoids for the treatment of oncology and central nervous system disorders.
The patent, secured by faculty members of George Mason University’s Institute for Biohealth Innovation and licensed by Targeted Pharmaceuticals, covers autophagy inhibitors as therapeutic compounds. The intellectual property was cultivated through a completed Phase 1/2 window trial for breast ductal carcinoma in situ (DCIS). The trial was conducted in collaboration between Drs. Virginia Espina and Lance Liotta of George Mason University, and Dr. Kirsten Edmiston of Inova Health System (PINC trial, clinicaltrials.gov identifier NCT01023477).
“The results of the PINC trial made it clear that our discovery had the potential to treat breast cancer before it spreads,” said Liotta, Co-Director & Co-Founder of the Center for Applied Proteomics and Molecular Medicine and professor at George Mason University’s College of Science.
In many conditions, such as neurodegenerative diseases, cancers, infectious diseases, and metabolic conditions, autophagy goes awry. In cancer especially, it can be a double-edged sword: it can suppress tumors by initiating cell death after exposure to cancer therapies, or it can actually help the cancer cells survive by allowing the recycling of cellular components to provide energy during severe stress.
Espina, a science research associate professor of the Center for Applied Proteomics and Molecular Medicine, has been investigating autophagy pathways for several years. “When we first started, it was under-appreciated that autophagy was used as a survival mechanism and not just a mechanism of cell death,” Espina said. Her team realized that if the autophagy pathway was interrupted, it could cause the cancer cells to die.